HIV Vaccine Conference

Save this PDF as:
 WORD  PNG  TXT  JPG

Size: px
Start display at page:

Download "HIV Vaccine Conference"

Transcription

1 HIV Vaccine Conference The B cell response to HIV and HIV vaccines: From broadly neutralizing to non-neutralizing antibodies In memory of Dr. Charles Mérieux Organized by Fondation Mérieux Les Pensières Fondation Mérieux Conference Center Veyrier du Lac - November 5 to 7,

2 Scientific Committee Members Brigitte Autran Françoise Barré-Sinoussi Jean-François Delfraissy Wayne Koff Yves Levy Gary Nabel Nina Russell Frederic Tangy Britta Wahren Institutions Pitié-Salpêtrière University Hospital, University Pierre and Marie Curie Pasteur Institute ANRS (Agence National de Recherche sur le Sida) Inserm Aviesan IAVI (International AIDS Vaccine Initiative) USA University Paris Est Vaccine Research Institute VRC (Vaccine Research Center) NIH (National Institutes of Health) USA Bill & Melinda Gates Foundation USA Pasteur Institute Karolinska Institute Sweden Steering Committee Members Marc P Girard Christophe Longuet Valentina Picot Institutions French National Academy of Medicine Fondation Mérieux Fondation Mérieux 2

3 Background Named after the One hundred guards of Emperess Eugenia from ( ), the Cent Gardes symposium was initiated in 1986 by Fondation Mérieux, the Pasteur Institute and Pasteur-Vaccins (which eventually fused with Institut Mérieux to become Pasteur Mérieux Serums and Vaccines, today Sanofi-Pasteur), with the drive and support of Dr Charles Mérieux. It is one of the very first international scientific conferences focusing on HIV/AIDS Vaccine research. First an annual then a bi-annual event, the meeting was initially held at the Marnes-la- Coquette near Paris, in the historical place where the 100 Guards were housed, after the event was moved to Annecy in After a few years of interruption, the meeting is back to life today at Les Pensières Conference Center, and we hope it will continue unabated in the years to come. The search for a safe and effective HIV vaccine began in the mid-1980, indeed a long journey with several ups and downs. In spite of more than a quarter of a century of hard work, successive attempts for developing a vaccine either have failed or provided only a modest short-lived protection. The quest for an HIV vaccine remains at this time a daunting challenge, but the identification of neutralization epitopes shared by most strains of virus and recognized by broadly neutralizing antibodies (bnabs) has given hope that one might eventually develop a valid protective immunogen. At the same time, there is increasing evidence that non-neutralizing antibodies (n-nabs) may play a pivotal role in vaccine-induced protection, a very different avenue that is worth investigating further. For these reasons, the 2012 conference will be devoted to the study of the B cell response to HIV infection and vaccines: from bnabs to n-nabs. We wish the meeting to be an opportunity for participants to share new findings, to open new collaborations, to generate new thinking and to identify novel promising areas for future research. 3

4 Objectives -To provide the state of the art on the B cell response to HIV infection, the role of antibodies in protection against HIV infection and the development of an effective B cell response through vaccination. -To describe current challenges and highlight new perspectives for the development of an effective HIV vaccine. -To allow high level exchange within the scientific community, foster comparisons between various vaccine models and strategies, create collaborative approaches and help them move forward. 4

5 November 5, :20-14:00 Registration Alain Mérieux 14:00-14:30 Welcome Addresses Jean-François Delfraissy Stanley Plotkin 14:30-14:35 In memory of Norman Letvin Brigitte Autran 14:35-14:45 Meeting Introduction Marc Girard SESSION I B cell responses to HIV: An overview Chair by: Marie-Paule Kieny & Jean François Delfraissy 14:45-15:35 Broadly neutralizing antibodies to HIV: an overview Dennis Burton 15:35-16:20 Maturation Pathways of HIV Non-Neutralizing Versus Broad Neutralizing Antibodies: Blueprints for Vaccine Design Barton Haynes 16:20-16:50 Coffee Break 16:50-17:35 Dissecting the human B cell response to pathogens Antonio Lanzavecchia SESSION II 17:40-18:00 Biology of the B cell Chair by: Jim Bradac & Stanley Plotkin Dynamic imaging of lymphocyte activation - from single molecule to living tissue Facundo Batista 18:00-18:20 Fc effector functions Jeffrey Ravetch 18:20-18:40 Driving factors and consequences of B cell dysfunctions during HIV-1 infection sca Chiodi 18:40-19:00 Panel Discussion 19:00 Welcome Dinner 5

6 November 6, 2012 SESSION III The B cell system Chair by: Gabriella Scarlatti & Julie Overbaugh 08:45-09:05 Autoreactive B cells in HIV infection and control Ignacio Sanz 09:05-09:25 09:25-09:45 Complexity of human antibody repertoires, as revealed by high throughput sequence analysis Extensive Somatic Hypermutation in Broadly Neutralizing HIV- 1 Antibodies: the Cart or the Horse? James Crowe Garnett Kelsoe 09:45-10:05 Innate pathway for Human Ab production Michel C. Nussenzweig 10:05-10:25 Panel Discussion 10:25-10:55 Coffee Break SESSION IV 10:55-11:15 Broadly neutralizing Antibodies Chair by: Frederic Tangy & Bonnie Mathieson Neutralizing Antibody Responses in Human Clinical Trials of Candidate HIV-1 Vaccines David Montefiori 11:15-11:35 HIV vaccine design to induce broadly-neutralizing antibodies William Schief 11:35-11:55 Deep Sequencing and the Evolution of the HIV-1 Neutralizing Antibody Response John Mascola 11:55-12:15 Panel Discussion 12:15-14:00 Lunch SESSION V HIV-1 broadly neutralizing antibodies epitopes Chair by: Marie Pancera & Quentin Sattentau 14:00-14:20 HIV- 1 broadly neutralizing epitopes: The CD4-binding site Peter Kwong 14:20-14:40 Development of broadly neutralizing antibody specificities Pascal Poignard 14:40-15:10 Broadly Neutralizing Antibodies to the HIV-1 Glycan Shield Ian Wilson 15:10-15:30 MPER-directed Antibodies from Patients with Broad and Potent Neutralizing Sera Mark Connors 15:30-15:50 Panel Discussion 15:50-16:30 Coffee Break 6

7 SESSION VI Induction of a broadly neutralizing antibodies response 16:30-16:50 Chair by: Nina Russell & Geppi Pantaleo Broadly Neutralizing Abs for HIV: Immunogen Design and Passive Transfer Gary Nabel 16:50-17:10 Llamas, vaccines and microbicides Robin Weiss 17:10-17:30 Immunoprophylaxis By Gene Transfer: Shortcut To An HIV Vaccine Philip Johnson 17:30-17:50 AAV-8-Mediated Delivery of Broadly Neutralizing Antibodies David Baltimore 17:50-18:10 Panel Discussion SESSION VII Round Table Discussion: The future of clinical efficacy trials Moderator: Gary Nabel 18:10-19:20 Participants: Nina Russell Harriet Robinson Geppi Pantaleo Britta Wahren 19:30 Dinner November 7, 2012 SESSION VIII 08:30-08:50 08:50-09:10 09:10-09:30 Nonneutralizing Antibodies Chair by: Britta Wahren & Francis Barin V2-dependent binding and neutralizing antibodies in HIV-1 subtype C infection Induction of HIV-1 Specific Mucosal Antibodies: AHI and Vaccination In depth characterization of in vitro Ab inhibitory activities and correlates with in vivo protection Lynn Morris Georgia Tomaras Christiane Moog 09:30-09:50 Fc Receptors and Lentivirus Infection Don Forthal 09:50-10:10 Panel Discussion 10:10-10:50 Coffee Break 7

8 SESSION IX Mucosal Immunity Chair by: Mario Clerici & Julie McElrath 10:50-11:10 Mucosal Barriers to HIV in the Female and Male Genital Tract Minh Dinh 11:10-11:30 11:30-11:50 Mucosal antibodies targeting gp41 for blocking mucosal entry of HIV-1 Virosome-gp41 induces mucosal antibodies that may act as front line defense against HIV-1 entry Morgane Bomsel Sylvain Fleury 11:50-12:10 Moving beyond the RV144 Thai Phase III trial Barton Haynes 12:10-12:30 Panel Discussion 12:30-14:00 Lunch SESSION X 14:00-14:20 14:20-14:40 Animal models Chair by: Shiu Luk Hu & Roger Le Grand Broadly neutralizing Abs generated by SHIV infection in macaques Elicitation of potent systemic and mucosal immune responses against HIV using self-amplifying RNA vaccines Malcom Martin Susan Barnett 14:40-15:00 Novel HIV Vaccine Strategies Dan Barouch 15:00-15:20 The SIVmac251 macaque model recapitulates the protection observed in RV144: immune correlates of protection Veffa Franchini 15:20-15:30 Passive Immunization with IgA Ruth Ruprecht 15:30-15:40 Panel Discussion 15:40-16:30 Coffee Break SESSION XI Conclusions Chair by: Jose Esparza & Patrice Debré 16:30-16:50 Meeting Review Françoise Barré Sinoussi 16:50-17:00 Concluding Remarks Marc Girard End of the Meeting 8

9 9

Cent Gardes Conference: HIV Vaccines. Organized by Fondation Mérieux «Les Pensières» Fondation Mérieux Conference Center Veyrier du Lac - France

Cent Gardes Conference: HIV Vaccines. Organized by Fondation Mérieux «Les Pensières» Fondation Mérieux Conference Center Veyrier du Lac - France Cent Gardes Conference: HIV Vaccines Organized by Fondation Mérieux «Les Pensières» Fondation Mérieux Conference Center Veyrier du Lac - October 6 to 8, 2017 Steering Committee Members Françoise Barré-Sinoussi

More information

Cent Gardes Conference: HIV Vaccines. Organized by Fondation Mérieux Les Pensières Center for Global Health Veyrier du Lac - France

Cent Gardes Conference: HIV Vaccines. Organized by Fondation Mérieux Les Pensières Center for Global Health Veyrier du Lac - France Cent Gardes Conference: HIV Vaccines Organized by Fondation Mérieux Les Pensières Center for Global Health Veyrier du Lac - October 6th to 8th, 2017 Steering Committee Members Françoise Barré-Sinoussi

More information

HIV: RV 144 prime boost HIV vaccine efficacy study

HIV: RV 144 prime boost HIV vaccine efficacy study HIV: RV 144 prime boost HIV vaccine efficacy study Nelson L. Michael, M.D., Ph.D Colonel, Medical Corps, U.S. Army Director US Military HIV Research Program (MHRP) Walter Reed Army Institute of Research

More information

Establishment and Targeting of the Viral Reservoir in Rhesus Monkeys

Establishment and Targeting of the Viral Reservoir in Rhesus Monkeys Establishment and Targeting of the Viral Reservoir in Rhesus Monkeys Dan H. Barouch, M.D., Ph.D. Center for Virology and Vaccine Research Beth Israel Deaconess Medical Center Ragon Institute of MGH, MIT,

More information

Immunogens and Antigen Processing: Report from a Global HIV Vaccine Enterprise Working Group

Immunogens and Antigen Processing: Report from a Global HIV Vaccine Enterprise Working Group report Immunogens and Antigen Processing: Report from a Global HIV Vaccine Enterprise Working Group John Mascola, C Richter King & Ralph Steinman on behalf of a Working Group convened by the Global HIV

More information

Lynn Morris. "Plan B"- bnabs for HIV prevention

Lynn Morris. Plan B- bnabs for HIV prevention "Plan B"- bnabs for HIV prevention Lynn Morris National Institute for Communicable Diseases, a division of the National Health Laboratory Service (NHLS) of South Africa, University of the Witwatersrand,

More information

Should There be Further Efficacy Testing of T-T cell Based Vaccines that do not Induce Broadly Neutralizing Antibodies?

Should There be Further Efficacy Testing of T-T cell Based Vaccines that do not Induce Broadly Neutralizing Antibodies? Dale and Betty Bumpers Vaccine Research Center National Institute of Allergy and Infectious Diseases National Institutes of Health Department of Health and Human Services Should There be Further Efficacy

More information

Progress in HIV Vaccine Development Magdalena Sobieszczyk, MD, MPH. Division of Infectious Diseases Columbia University Medical Center

Progress in HIV Vaccine Development Magdalena Sobieszczyk, MD, MPH. Division of Infectious Diseases Columbia University Medical Center Progress in HIV Vaccine Development Magdalena Sobieszczyk, MD, MPH Division of Infectious Diseases Columbia University Medical Center 1 Outline A short history of HIV vaccine design and development Describe

More information

Current Strategies in HIV-1 Vaccine Development Using Replication-Defective Adenovirus as a Case Study

Current Strategies in HIV-1 Vaccine Development Using Replication-Defective Adenovirus as a Case Study Note: I have added some clarifying comments to the slides -- please click on Comments under View to see them. Current Strategies in HIV-1 Vaccine Development Using Replication-Defective Adenovirus as a

More information

HIV and Challenges of Vaccine Development

HIV and Challenges of Vaccine Development Dale and Betty Bumpers Vaccine Research Center National Institute of Allergy and Infectious Diseases National Institutes of Health HIV and Challenges of Vaccine Development Richard A. Koup, MD INTEREST

More information

Isolation of a Broadly Neutralizing Antibody with Low Somatic Mutation from a Chronically Infected HIV-1 Patient

Isolation of a Broadly Neutralizing Antibody with Low Somatic Mutation from a Chronically Infected HIV-1 Patient Isolation of a Broadly Neutralizing Antibody with Low Somatic Mutation from a Chronically Infected HIV-1 Patient Amanda Fabra García, Carolina Beltrán Pavez, Alberto Merino Mansilla, Cristina Xufré, Isabel

More information

27-28 November, 2017 Paris, France Espace Saint-Martin

27-28 November, 2017 Paris, France Espace Saint-Martin 27-28 November, 2017 Paris, France Espace Saint-Martin 199 bis rue Saint-Martin, 75003 Paris Immuno-oncology research and the subsequent development of immunotherapies continue to progress rapidly. We

More information

HVTN Laboratory Program: Immunogenicity and Research Assays

HVTN Laboratory Program: Immunogenicity and Research Assays HVTN Laboratory Program: Immunogenicity and Research Assays Erica Andersen-Nissen, PhD Director, Cape Town HVTN Immunology Laboratory Considerations for a Pan-African HIV Vaccine Development Agenda Kigali,

More information

CHARITY DINNER LINK FOR AIDES DEC PAVILLON CAMBON PARIS FRANCE

CHARITY DINNER LINK FOR AIDES DEC PAVILLON CAMBON PARIS FRANCE CHARITY LINK FOR AIDES DEC 11.2017 PAVILLON CAMBON PARIS FRANCE AURÉLIEN BEAUCAMP PRESIDENT OF AIDES MICHEL SIMON PRESIDENT OF LINK CORDIALLY INVITE YOU TO THE CHARITY LINK FOR AIDES IN THE PRESENCE OF

More information

Novel Vaccine Products for Planned Phase I Immunogenicity Studies in Infants

Novel Vaccine Products for Planned Phase I Immunogenicity Studies in Infants Office of AIDS Research Novel Vaccine Products for Planned Phase I Immunogenicity Studies in Infants L. Jean Patterson, PhD Office of AIDS Research, NIH February 7, 2017 Office of AIDS Research OAR Responsibilities

More information

Virus Panels for Assessing Vaccine-Elicited Neutralizing Antibodies

Virus Panels for Assessing Vaccine-Elicited Neutralizing Antibodies Virus Panels for Assessing Vaccine-Elicited Neutralizing Antibodies Michael Seaman, Ph.D. Center for Virology and Vaccine Research Beth Israel Deaconess Medical Center Harvard Medical School J. Virol.

More information

The Collaboration for AIDS Vaccine Discovery. 10th Annual Meeting. Grantee Profiles. December 7 9, 2015 Seattle, Washington

The Collaboration for AIDS Vaccine Discovery. 10th Annual Meeting. Grantee Profiles. December 7 9, 2015 Seattle, Washington The Collaboration for AIDS Vaccine Discovery 10th Annual Meeting Profiles December 7 9, 2015 Seattle, Washington Table of Contents Ackerman/Alter: Leveraging Antibody Effector Function 4 Alter: A Genetic

More information

Broad and Potent Neutralizing Antibodies from an African Donor Reveal a New HIV-1 Vaccine Target

Broad and Potent Neutralizing Antibodies from an African Donor Reveal a New HIV-1 Vaccine Target Broad and Potent Neutralizing Antibodies from an African Donor Reveal a New HIV-1 Vaccine Target Laura M. Walker, 1 * Sanjay K. Phogat, 2 * Po-Ying Chan-Hui, 3 Denise Wagner, 2 Pham Phung, 4 Julie L. Goss,

More information

Dirk Heinz, Helmholtz Centre for Infection Research, Germany SESSION I: INDIVIDUALIZED MEDICINE TODAY AND TOMORROW

Dirk Heinz, Helmholtz Centre for Infection Research, Germany SESSION I: INDIVIDUALIZED MEDICINE TODAY AND TOMORROW PRELIMINARY PROGRAM (all academic titles have been omitted) Thursday, June 21, 2018 3.30 p.m. Start of the conference OPENING ADDRESSES Wilhelm Krull, Volkswagen Foundation, Germany Christopher Baum, Medical

More information

HVTN P5 Vaccine Trials

HVTN P5 Vaccine Trials HVTN P5 Vaccine Trials Erica Andersen-Nissen, PhD Director, Cape Town HVTN Immunology Laboratory Considerations for a Pan-African HIV Vaccine Development Agenda Kigali, Rwanda 16-17 March 2015 HVTN Mission

More information

Spike Trimer RNA. dsdna

Spike Trimer RNA. dsdna Spike Trimer RNA dsdna Spike Trimer RNA Spike trimer subunits xxx gp120: receptor and coreceptor binding xxxxxxx gp41: membrane anchoring and target cell fusion dsdna Spike Trimer HIV gp120 binds to host

More information

Towards a New Era in Dermocosmetics

Towards a New Era in Dermocosmetics 3 rd ISM Symposium on Skin Microbiota 2018 Towards a New Era in Dermocosmetics June 15, 2018 - Paris, France The International Society of Microbiota (ISM) organizes three meetings in 2018, one ISM annual

More information

Induction of Immunity to Human Immunodeficiency Virus Type-1 by Vaccination

Induction of Immunity to Human Immunodeficiency Virus Type-1 by Vaccination Induction of Immunity to Human Immunodeficiency Virus Type-1 by Vaccination M. Juliana McElrath 1, * and Barton F. Haynes 2, * 1 Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research

More information

5 th Annual GABRIEL meeting 9-12 December, 2012 Les Pensières, Annecy, France

5 th Annual GABRIEL meeting 9-12 December, 2012 Les Pensières, Annecy, France 5 th Annual GABRIEL meeting 9-12 December, 2012 Les Pensières, Annecy, Organized by Fondation Mérieux With the participation of the «Réseau Science et Technique, Afrique Caraïbes de soutien à la lutte

More information

Asier Sáez-Cirión, PhD Unité de Régulation des Infections Rétrovirales Institut Pasteur, Paris, France

Asier Sáez-Cirión, PhD Unité de Régulation des Infections Rétrovirales Institut Pasteur, Paris, France Infection à VIH : une rémission possible Asier Sáez-Cirión, PhD Unité de Régulation des Infections Rétrovirales Institut Pasteur, Paris, France Viral reservoirs persist in HIV-infected individuals receiving

More information

Antibody gene transfer for HIV immunoprophylaxis

Antibody gene transfer for HIV immunoprophylaxis Antibody gene transfer for HIV immunoprophylaxis Alejandro B Balazs & Anthony P West Jr Antibody gene transfer, which involves the delivery of genes that encode potent, broadly neutralizing antibodies

More information

What are ADCC antibodies? Work on influenza ADCC antibodies Greenberg et al, Hashimoto et al. First describes Fluspecific

What are ADCC antibodies? Work on influenza ADCC antibodies Greenberg et al, Hashimoto et al. First describes Fluspecific 14/7/214 Acknowledgement antibodies against diverse influenza strains: Implications for universal vaccination Sinth Jegaskanda PhD Prof Stephen Kent University of Melbourne What are antibodies? Work on

More information

Development of live attenuated pediatric RSV vaccines

Development of live attenuated pediatric RSV vaccines Development of live attenuated pediatric RSV vaccines Laboratory of Infectious Diseases, NIAID, NIH (Ursula Buchholz, Peter Collins) Center for Immunization Research, JHU (Ruth Karron) Infant with RSV

More information

CROI 2016 Review: Immunology and Vaccines

CROI 2016 Review: Immunology and Vaccines Frontier AIDS Education and Training Center CROI 2016 Review: Immunology and Vaccines Meena Ramchandani MD MPH Acting Instructor, University of Washington March 2016 This presentation is intended for educational

More information

A global approach to HIV-1 vaccine development

A global approach to HIV-1 vaccine development A global approach to HIV-1 vaccine development The Harvard community has made this article openly available. Please share how this access benefits you. Your story matters. Citation Published Version Accessed

More information

Dirk Heinz, Helmholtz Centre for Infection Research, Germany SESSION I: INDIVIDUALIZED MEDICINE TODAY AND TOMORROW

Dirk Heinz, Helmholtz Centre for Infection Research, Germany SESSION I: INDIVIDUALIZED MEDICINE TODAY AND TOMORROW PRELIMINARY PROGRAM (all academic titles have been omitted) Thursday, June 21, 2018 3.30 p.m. Start of the conference OPENING ADDRESSES Wilhelm Krull, Volkswagen Foundation, Germany Christopher Baum, Medical

More information

A Blueprint for HIV Vaccine Discovery

A Blueprint for HIV Vaccine Discovery A Blueprint for HIV Vaccine Discovery Dennis R. Burton, Scripps Research Institute Rafi Ahmed, Emory University Dan H. Barouch, Beth Israel Deaconess Medical Center Salvatore T. Butera, Scripps Research

More information

Second China-U.S. Workshop on the Challenges of Emerging Infections, Laboratory Safety and Global Health Security

Second China-U.S. Workshop on the Challenges of Emerging Infections, Laboratory Safety and Global Health Security Second China-U.S. Workshop on the Challenges of Emerging Infections, Laboratory Safety and Global Health Security May 17-19 2017, Wuhan, China Meeting Program Note: Each report will take 25 minutes including

More information

DEBATE ON HIV ENVELOPE AS A T CELL IMMUNOGEN HAS BEEN GAG-GED

DEBATE ON HIV ENVELOPE AS A T CELL IMMUNOGEN HAS BEEN GAG-GED DEBATE ON HIV ENVELOPE AS A T CELL IMMUNOGEN HAS BEEN GAG-GED Viv Peut Kent Laboratory, University of Melbourne, Australia WHY ENVELOPE? Env subject to both humoral and cellular immune responses Perhaps

More information

First Scientific Symposium Translational Research in Alzheimer. Paris - September 18, 2009 Collège de France

First Scientific Symposium Translational Research in Alzheimer. Paris - September 18, 2009 Collège de France First Scientific Symposium Translational Research in Alzheimer Paris - September 18, 2009 Collège de France 8h30 Welcome coffee 9h-9h30 Opening remarks - Philippe Lagayette, President of French National

More information

Trial Objectives immunogenicity safety

Trial Objectives immunogenicity safety Optimal priming of poxvirus vector (NYVAC)-based HIV vaccine regimens requires 3 DNA injections. Long term Results of the EV03/ANRS Vac20 Phase I/II Trial. Yves Levy, Kim Ellefsen, Wolfgang Stöehr, Pierre-Alexandre

More information

HIV Anti-HIV Neutralizing Antibodies

HIV Anti-HIV Neutralizing Antibodies ,**/ The Japanese Society for AIDS Research The Journal of AIDS Research : HIV HIV Anti-HIV Neutralizing Antibodies * Junji SHIBATA and Shuzo MATSUSHITA * Division of Clinical Retrovirology and Infectious

More information

Update on Biomedical Prevention. Thomas C. Quinn, MD, MSc

Update on Biomedical Prevention. Thomas C. Quinn, MD, MSc Update on Biomedical Prevention Thomas C. Quinn, MD, MSc Associate Director of International Research National Institute of Allergy and Infectious Diseases Director, Johns Hopkins Center for Global Health

More information

Madrid March Manuel Hidalgo. Alberto Bardelli. Lillian Siu. Josep Tabernero. Application deadline February 23 rd

Madrid March Manuel Hidalgo. Alberto Bardelli. Lillian Siu. Josep Tabernero. Application deadline February 23 rd Spanish National Cancer Research Centre CNIO Frontiers Meetings 2015 Madrid 22 25 March 2015 New Trends in Anticancer Drug Development Application deadline February 23 rd Organisers Manuel Hidalgo Alberto

More information

Challenges in Designing HIV Env Immunogens for Developing a Vaccine

Challenges in Designing HIV Env Immunogens for Developing a Vaccine b514_chapter-13.qxd 12/4/2007 3:39 PM Page 327 Chapter 13 Challenges in Designing HIV Env Immunogens for Developing a Vaccine Indresh K. Srivastava* and R. Holland Cheng Summary HIV continues to be a major

More information

2015 Towards an HIV Cure Symposium 18 & 19 July 2015 Hyatt Regency Hotel, Vancouver, Canada

2015 Towards an HIV Cure Symposium 18 & 19 July 2015 Hyatt Regency Hotel, Vancouver, Canada 2015 Towards an HIV Cure Symposium 18 & 19 July 2015 Hyatt Regency Hotel, Vancouver, Canada Saturday 18 th July 08h30 09h00 09h00 09h20 09h20 9h50 9h50 10h05 Opening Keynote Community Registration Welcome

More information

Salivary mucinmuc5b inhibits HIV-1 subtype C in an in vitro pseudoviral assay

Salivary mucinmuc5b inhibits HIV-1 subtype C in an in vitro pseudoviral assay Salivary mucinmuc5b inhibits HIV-1 subtype C in an in vitro pseudoviral assay Julia Peacocke, Zoe Lotz, Jeffrey R Dorfman 1, Delawir Kahn, Paul Roux 2 and Anwar S Mall* Division of General Surgery and

More information

It has been 25 years since HIV-1 was identified as the causative

It has been 25 years since HIV-1 was identified as the causative Vol 4j2 October 8jdoi:.38/nature732 Challenges in the development of an HIV-1 vaccine Dan H. Barouch 1 The development of a safe and effective human immunodeficiency virus (HIV)-1 vaccine is a critically

More information

UNICEF 2017 VACCINE INDUSTRY CONSULTATION October 2017 UNICEF Supply Division, Oceanvej 10-12, 2150, Nordhavn, Copenhagen, Denmark

UNICEF 2017 VACCINE INDUSTRY CONSULTATION October 2017 UNICEF Supply Division, Oceanvej 10-12, 2150, Nordhavn, Copenhagen, Denmark UNICEF 2017 VACCINE INDUSTRY CONSULTATION 05-06 October 2017 UNICEF Supply Division, Oceanvej 10-12, 2150, Nordhavn, Copenhagen, Denmark AGENDA INTRODUCTION UNICEF works in 190 countries and territories

More information

Boosts Following Priming with gp120 DNA

Boosts Following Priming with gp120 DNA Neutralizing Antibody Responses Induced with V3-scaffold Protein Boosts Following Priming with gp120 DNA Susan Zolla-Pazner NYU School of Medicine Problems with Whole Env Immunogens Poor induction of Abs

More information

The Humoral Response to HIV-1: New Insights, Renewed Focus

The Humoral Response to HIV-1: New Insights, Renewed Focus SUPPLEMENT ARTICLE The Humoral Response to HIV-1: New Insights, Renewed Focus Galit Alter 1 and M. Anthony Moody 2 1 Ragon Institute of MGH, Massachusetts Institute of Technology and Harvard University;

More information

Adaptive Immunity. Lecture 14 Biology W3310/4310 Virology Spring Life is simple, but we insist on making it complicated CONFUCIUS

Adaptive Immunity. Lecture 14 Biology W3310/4310 Virology Spring Life is simple, but we insist on making it complicated CONFUCIUS Adaptive Immunity Lecture 14 Biology W3310/4310 Virology Spring 2016 Life is simple, but we insist on making it complicated CONFUCIUS Host defenses Intrinsic - Always present in the uninfected cell - Apoptosis,

More information

Chapter 23 Immunity Exam Study Questions

Chapter 23 Immunity Exam Study Questions Chapter 23 Immunity Exam Study Questions 1. Define 1) Immunity 2) Neutrophils 3) Macrophage 4) Epitopes 5) Interferon 6) Complement system 7) Histamine 8) Mast cells 9) Antigen 10) Antigens receptors 11)

More information

The HIV Prevention Toolbox: More Tools Needed

The HIV Prevention Toolbox: More Tools Needed The HIV Prevention Toolbox: More Tools Needed Z Mike Chirenje MD FRCOG University of Zimbabwe, College of Health Sciences, Dept. of Obstetrics and Gynaecology Avondale, Harare, Zimbabwe chirenje@uz-ucsf.co.zw

More information

Active and Passive Immunization for Avian Influenza Virus Infections

Active and Passive Immunization for Avian Influenza Virus Infections NIAID Active and Passive Immunization for Avian Influenza Virus Infections Kanta Subbarao, MD, MPH Laboratory of Infectious Diseases NIAID, NIH Immortalizing H5 HA-Specific Memory B Cells Collection of

More information

NASDAQ:NVAX Novavax, Inc. All rights reserved.

NASDAQ:NVAX Novavax, Inc. All rights reserved. Novavax vaccine induced improved immune responses against homologous and drifted A(H3N2) viruses in older adults compared to egg-based, high-dose, influenza vaccine World Vaccine Congress April 4, 2018

More information

Chapter 35 Active Reading Guide The Immune System

Chapter 35 Active Reading Guide The Immune System Name: AP Biology Mr. Croft Chapter 35 Active Reading Guide The Immune System Section 1 Phagocytosis plays an important role in the immune systems of both invertebrates and vertebrates. Review the process

More information

Alabama Vaccine Research Clinic. Clinical Research Trials Guide: Vaccines & Microbicides. University of Alabama at Birmingham

Alabama Vaccine Research Clinic. Clinical Research Trials Guide: Vaccines & Microbicides. University of Alabama at Birmingham Alabama Vaccine Research Clinic Clinical Research Trials Guide: Vaccines & Microbicides University of Alabama at Birmingham Introduction About the AVRC Since 1994, the Alabama Vaccine Research Clinic (AVRC)

More information

Broadly Neutralizing Antibodies for HIV Eradication

Broadly Neutralizing Antibodies for HIV Eradication DOI 10.1007/s11904-016-0299-7 HIV PATHOGENESIS AND TREATMENT (AL LANDAY, SECTION EDITOR) Broadly Neutralizing Antibodies for HIV Eradication Kathryn E. Stephenson 1,2 & Dan H. Barouch 1,2 # The Author(s)

More information

Fondation Mérieux Mission and Activities

Fondation Mérieux Mission and Activities Fondation Mérieux Mission and Activities Testes de Diagnóstico in Vitro Acessíveis e com Qualidade Assegurada para Programas de Saúde Pública Brazil April 2012 JF de Lavison MISSION Strengthen local capacities

More information

Association Between HIV-1 Coreceptor Usage and Resistance to Broadly Neutralizing Antibodies

Association Between HIV-1 Coreceptor Usage and Resistance to Broadly Neutralizing Antibodies BASIC AND TRANSLATIONAL SCIENCE Association Between HIV-1 Coreceptor Usage and Resistance to Broadly Neutralizing Antibodies Nico Pfeifer, Dr,* Hauke Walter, MD, and Thomas Lengauer, Dr, PhD* Background:

More information

Research in viral hepatitis: the French ANRS experience

Research in viral hepatitis: the French ANRS experience PARIS HEPATITIS CONFERENCE January 14-15, 2013 Research in viral hepatitis: the French ANRS experience Pr. Jean-François DELFRAISSY Director of ANRS Internal Medicine Department CHU Bicêtre Paris XI -

More information

LBL 3 terms/discussion questions posted BNG Seminar Monday! Lippman 017, Common Hour (w/ lunch) Julie Czupryna, Ph.D.

LBL 3 terms/discussion questions posted BNG Seminar Monday! Lippman 017, Common Hour (w/ lunch) Julie Czupryna, Ph.D. The Immune System Some updates LBL 3 terms/discussion questions posted BNG Seminar Monday! Lippman 017, Common Hour (w/ lunch) Julie Czupryna, Ph.D. Technical Director, Optical Imaging Core, Upenn Beyond

More information

HIV Prophylactic Vaccine Development Program

HIV Prophylactic Vaccine Development Program HIV Prophylactic Vaccine Development Program Maria Grazia Pau Senior Director, Compound Development Team Leader, Janssen AVAC Webinar, 28 April 2017 HIV vaccine R&D programs: Current Collaborators (in

More information

TOWARDS A UNIVERSAL INFLUENZA VIRUS VACCINE

TOWARDS A UNIVERSAL INFLUENZA VIRUS VACCINE TOWARDS A UNIVERSAL INFLUENZA VIRUS VACCINE Peter Palese Icahn School of Medicine at Mount Sinai New York OPTIONS IX 8-26-16 ISIRV - Options IX for the Control of Influenza Peter Palese, PhD Professor

More information

Chapter 5. Generation of lymphocyte antigen receptors

Chapter 5. Generation of lymphocyte antigen receptors Chapter 5 Generation of lymphocyte antigen receptors Structural variation in Ig constant regions Isotype: different class of Ig Heavy-chain C regions are encoded in separate genes Initially, only two of

More information

Residual Cancer. May 3-5, International Symposium. on Minimal. Le Corum. > Preliminary. Program MONTPELLIER, FRANCE

Residual Cancer. May 3-5, International Symposium. on Minimal. Le Corum. > Preliminary. Program MONTPELLIER, FRANCE International Symposium th on Minimal Residual Cancer > Preliminary Program May 3-5, 2018 Le Corum MONTPELLIER, FRANCE Organizers: www.ismrc2018.com > Committee & Speakers > Welcome to Montpellier Scientific

More information

ANRS CO12 CIRVIR - Prospective cohort involving patients with viral cirrhosis B and C

ANRS CO12 CIRVIR - Prospective cohort involving patients with viral cirrhosis B and C ANRS CO12 CIRVIR - Prospective cohort involving patients with viral cirrhosis B and C Head : Nahon Pierre, Service d'hépatologie, Hôpital Jean Verdier Roudot-thoraval Françoise, Service de santé publique,

More information

Section Lectures: Immunology/Virology Time: 9:00 am 10:00 am LRC 105 A & B

Section Lectures: Immunology/Virology Time: 9:00 am 10:00 am LRC 105 A & B Section Director: Cliff Bellone, Ph.D. Office: Doisy Hall - R 405 Phone: 577-8449 E-Mail: bellonec@slu.edu Lecturers: James Swierkosz, Ph.D. Office: Medical School Rm. 412 Phone: 577-8430 E-Mail: swierkoszje@slu.edu

More information

Chapter 22: The Lymphatic System and Immunity

Chapter 22: The Lymphatic System and Immunity Bio40C schedule Lecture Immune system Lab Quiz 2 this week; bring a scantron! Study guide on my website (see lab assignments) Extra credit Critical thinking questions at end of chapters 5 pts/chapter Due

More information

Professor Brigitte Autran

Professor Brigitte Autran 16 th Annual Resistance and Antiviral Professor Brigitte Autran Centre Hospitalier Universitaire Pitié-Salpétrière, Paris, France Thursday 20 September 2012, Wellcome Collection Conference Centre, London

More information

The potential role of PD-1/PD-L1 blockade in HIV Remission and Cure Strategies

The potential role of PD-1/PD-L1 blockade in HIV Remission and Cure Strategies The potential role of PD-1/PD-L1 blockade in HIV Remission and Cure Strategies Stephen Mason Director, Discovery Virology Bristol-Myers Squibb Community Cure Workshop 2015 Sunday, Feb 22, 2015 Seattle,

More information

Identification and Characterization of CD4 T cells actively transcribing HIV RNA in Peripheral Blood

Identification and Characterization of CD4 T cells actively transcribing HIV RNA in Peripheral Blood Dale and Betty Bumpers Vaccine Research Center National Institute of Allergy and Infectious Diseases National Institutes of Health Identification and Characterization of CD4 T cells actively transcribing

More information

The History of HIV Vaccine Development

The History of HIV Vaccine Development The History of HIV Vaccine Development a short story on 30 years of research å Dr. Jill Gilmour International AIDS Vaccine Initiative Barcelona, 6 October 2013 IAVI is a product-development partnership

More information

Unlocking HIV 1 Env: implications for antibody attack

Unlocking HIV 1 Env: implications for antibody attack DOI 10.1186/s12981-017-0168-5 AIDS Research and Therapy REVIEW Open Access Unlocking HIV 1 Env: implications for antibody attack Jonathan Richard 1,2, Shilei Ding 1,2 and Andrés Finzi 1,2,3* Abstract Collective

More information

Vasilis Vasiliou. Q. Max Guo. Alcohol and Cancer

Vasilis Vasiliou. Q. Max Guo. Alcohol and Cancer Alcohol and Cancer Samir Zakhari Editors Vasilis Vasiliou Q. Max Guo Alcohol and Cancer Editors Samir Zakhari, Ph.D. Director Division of Metabolism and Health Effects National Institute on Alcohol Abuse

More information

April 28 th -29 th,2017 New Delhi, India

April 28 th -29 th,2017 New Delhi, India INTERNATIONAL SYMPOSIUM ONDENGUE, ZIKA AND CHIKUNGUNYA: CONTROL AND PREVENTION: EXPECTATIONS AND CHALLENGES April 28 th -29 th,2017 New Delhi, India Venue: Dr Ramalingaswamy Board Room, AIIMS Ansari Nagar

More information

A VACCINE FOR HIV BIOE 301 LECTURE 10 MITALI BANERJEE HAART

A VACCINE FOR HIV BIOE 301 LECTURE 10 MITALI BANERJEE HAART BIOE 301 LECTURE 10 MITALI BANERJEE A VACCINE FOR HIV HIV HAART Visit wikipedia.org and learn the mechanism of action of the five classes of antiretroviral drugs. (1) Reverse transcriptase inhibitors (RTIs)

More information

Immunology The innate and adaptive immune systems

Immunology The innate and adaptive immune systems Immunology The innate and adaptive immune systems The immune system is the collection of cells, tissues and molecules that protects the body from numerous pathogenic microbes and toxins in our environment.

More information

BEAT-HIV Delaney Collaboratory to Cure HIV-1 Infection by Combination Immunotherapy

BEAT-HIV Delaney Collaboratory to Cure HIV-1 Infection by Combination Immunotherapy BEAT-HIV Delaney Collaboratory to Cure HIV-1 Infection by Combination Immunotherapy We are pleased to announce that the National Institutes of Health (NIH) has awarded nearly $23 million to co-principal

More information

Immunotypes of a Quaternary Site of HIV-1 Vulnerability and Their Recognition by Antibodies

Immunotypes of a Quaternary Site of HIV-1 Vulnerability and Their Recognition by Antibodies JOURNAL OF VIROLOGY, May 2011, p. 4578 4585 Vol. 85, No. 9 0022-538X/11/$12.00 doi:10.1128/jvi.02585-10 Copyright 2011, American Society for Microbiology. All Rights Reserved. Immunotypes of a Quaternary

More information

2005 LANDES BIOSCIENCE. DO NOT DISTRIBUTE.

2005 LANDES BIOSCIENCE. DO NOT DISTRIBUTE. [Human Vaccines 1:2, 45-60; March/April 2005]; 2005 Landes Bioscience Review Role of Neutralizing Antibodies in Protective Immunity Against HIV Indresh K. Srivastava* Jeffrey B. Ulmer Susan W. Barnett

More information

October 27, 2017 DRAFT AGENDA

October 27, 2017 DRAFT AGENDA October 27, 2017 DRAFT AGENDA 8:00-8:30 AM Coffee and Registration 8:30-8:45 AM Welcome Patricia Kuszler, Director, Center for Law, Science and Global Health, University of Washington School of Law This

More information

Learning from the past: How prepared are we for future HIV vaccine efficacy trials in Uganda

Learning from the past: How prepared are we for future HIV vaccine efficacy trials in Uganda Learning from the past: How prepared are we for future HIV vaccine efficacy trials in Uganda Pontiano Kaleebu MRC-UVRI Uganda Research Unit on AIDS & UVRI-IAVI HIV Vaccine Programme Past 1987 Cohort studies

More information

Spontaneous Control of Viral Replication during Primary HIV Infection: When Is HIV Controller Status Established?

Spontaneous Control of Viral Replication during Primary HIV Infection: When Is HIV Controller Status Established? HIV/AIDS BRIEF REPORT Spontaneous Control of Viral Replication during Primary HIV Infection: When Is HIV Controller Status Established? Cécile Goujard, 1,2 Marie-Laure Chaix, 3 Olivier Lambotte, 1,2 Christiane

More information

Page 1. Principles of Human Immunology. Discipline Committee: Professor Allan Cripps Dr Karla Lemmert Emeritus Professor Jennifer Rolland

Page 1. Principles of Human Immunology. Discipline Committee: Professor Allan Cripps Dr Karla Lemmert Emeritus Professor Jennifer Rolland Module Code: Module Title: Module Convenor: Discipline Committee: IMM I Principles of Human Immunology Dr Karla Lemmert Emeritus Professor Jennifer Rolland Date Module Outline reviewed: November 14, 2006

More information

Gastric cancer: From bench to bedside

Gastric cancer: From bench to bedside EAGEN POSTGRADUATE COURSE Gastric cancer: From bench to bedside Nantes, France, Under auspices of the ESDO and EHMSD IMAD & DHU Oncogreffe, CHU de Nantes 17-18 June 2016 Local organiser Pr Tamara Matysiak-Budnik

More information

Heterologous Tier 1 R5 SHIV-C Challenges: Correlates of Protection

Heterologous Tier 1 R5 SHIV-C Challenges: Correlates of Protection Heterologous Tier 1 R5 SHIV-C Challenges: Correlates of Protection Enterprise Meeting: The Appropriate Use of Tiered Virus Panels when Assessing HIV-1 Vaccine-elicited Neutralizing Antibodies" July 7 th,

More information

October 25-26, Fifth Avenue 3rd Floor New York, NY (USA)

October 25-26, Fifth Avenue 3rd Floor New York, NY (USA) October 25-26, 2018 404 Fifth Avenue 3rd Floor New York, NY 10018 (USA) events@curepsp.org Join CurePSP and the PSP Association for the First International Research Symposium on PSP & CBD at the Royal

More information

RESTORATION OF VISION

RESTORATION OF VISION RESTORATION OF VISION Recent advances in basic and clinical vision research have made ophthalmology one of the most exciting fields of technological and therapeutic innovations. This 10th annual Ri.MED

More information

HEPATITIS B: are escape mutants of concern?

HEPATITIS B: are escape mutants of concern? VACCINATION: AN EVOLUTIONARY ENGINE FOR SPECIES? Fondation Mérieux Conference Centre Veyrier-du-Lac, France November 25-27, 2013 HEPATITIS B: are escape mutants of concern? Alessandro ZANETTI Department

More information

Cours Pasteur. Molecular Cancer Genetics. September 18-29, 2017

Cours Pasteur. Molecular Cancer Genetics. September 18-29, 2017 Cours Pasteur Molecular Cancer Genetics September 18-29, 2017 Directors François CLEMENT-BIDARD Co-director, Institut Curie Hospital Jean-Pierre VARTANIAN Co-director, Institut Pasteur PROGRAM 2017-2018

More information

Introduction to Immunology Part 2 September 30, Dan Stetson

Introduction to Immunology Part 2 September 30, Dan Stetson Introduction to Immunology Part 2 September 30, 2016 Dan Stetson stetson@uw.edu 441 Lecture #2 Slide 1 of 26 CLASS ANNOUNCEMENT PLEASE NO TREE NUTS IN CLASS!!! (Peanuts, walnuts, almonds, cashews, etc)

More information

I. Lines of Defense Pathogen: Table 1: Types of Immune Mechanisms. Table 2: Innate Immunity: First Lines of Defense

I. Lines of Defense Pathogen: Table 1: Types of Immune Mechanisms. Table 2: Innate Immunity: First Lines of Defense I. Lines of Defense Pathogen: Table 1: Types of Immune Mechanisms Table 2: Innate Immunity: First Lines of Defense Innate Immunity involves nonspecific physical & chemical barriers that are adapted for

More information

Medical Virology Immunology. Dr. Sameer Naji, MB, BCh, PhD (UK) Head of Basic Medical Sciences Dept. Faculty of Medicine The Hashemite University

Medical Virology Immunology. Dr. Sameer Naji, MB, BCh, PhD (UK) Head of Basic Medical Sciences Dept. Faculty of Medicine The Hashemite University Medical Virology Immunology Dr. Sameer Naji, MB, BCh, PhD (UK) Head of Basic Medical Sciences Dept. Faculty of Medicine The Hashemite University Human blood cells Phases of immune responses Microbe Naïve

More information

HIV-1 Vaccine Trials: Evolving Concepts and Designs

HIV-1 Vaccine Trials: Evolving Concepts and Designs Send Orders of Reprints at bspsaif@emirates.net.ae 274 The Open AIDS Journal, 2012, 6, 274-288 HIV-1 Vaccine Trials: Evolving Concepts and Designs Open Access Missa P. Sanou 1, Anne S. De Groot 2, Michael

More information

The Adaptive Immune Responses

The Adaptive Immune Responses The Adaptive Immune Responses The two arms of the immune responses are; 1) the cell mediated, and 2) the humoral responses. In this chapter we will discuss the two responses in detail and we will start

More information

Campbell's Biology: Concepts and Connections, 7e (Reece et al.) Chapter 24 The Immune System Multiple-Choice Questions

Campbell's Biology: Concepts and Connections, 7e (Reece et al.) Chapter 24 The Immune System Multiple-Choice Questions Campbell's Biology: Concepts and Connections, 7e (Reece et al.) Chapter 24 The Immune System 24.1 Multiple-Choice Questions 1) The body's innate defenses against infection include A) several nonspecific

More information

Chapter 1. Chapter 1 Concepts. MCMP422 Immunology and Biologics Immunology is important personally and professionally!

Chapter 1. Chapter 1 Concepts. MCMP422 Immunology and Biologics Immunology is important personally and professionally! MCMP422 Immunology and Biologics Immunology is important personally and professionally! Learn the language - use the glossary and index RNR - Reading, Note taking, Reviewing All materials in Chapters 1-3

More information

Diversifying the Pipeline of Product Concepts for an HIV Vaccine. RFP Overview and Guidelines

Diversifying the Pipeline of Product Concepts for an HIV Vaccine. RFP Overview and Guidelines Diversifying the Pipeline of Product Concepts for an HIV Vaccine RFP Overview and Guidelines 1 Table of Contents 1. Introduction. 3 2. Background a. Foundation s HIV Vaccine Strategy 3 b. CAVD Framework..

More information

Soup Kitchen Team. 1-Jan Barbara Kuhn

Soup Kitchen Team. 1-Jan Barbara Kuhn Soup Kitchen 2012 Dates Team Phone# 1-Jan Barbara Kuhn 342-1347 8-Jan Lynne Eckerle 376-6702 David & Denise Rau 378-3457 Mike & Kathleen Proffit 378-5957 Jean Ozols 376-6674 15-Jan Dan & Jill Prestel 342-9187

More information

NIAID Vaccine Research Center: A Mission to Prevent HIV Infection

NIAID Vaccine Research Center: A Mission to Prevent HIV Infection NIAID Vaccine Research Center: A Mission to Prevent HIV Infection AIDS Vaccine Awareness Day 20 year anniversary May 18, 2017 Barney S. Graham, MD, PhD Deputy Director Origins of the VRC 1997 1998

More information

Global Panel of HIV-1 Env Reference Strains for Standardized Assessments of Vaccine- Elicited Neutralizing Antibodies

Global Panel of HIV-1 Env Reference Strains for Standardized Assessments of Vaccine- Elicited Neutralizing Antibodies JVI Accepts, published online ahead of print on 18 December 2013 J. Virol. doi:10.1128/jvi.02853-13 Copyright 2013, American Society for Microbiology. All Rights Reserved. 1 2 Global Panel of HIV-1 Env

More information

News Letter. Thanks letter AOCC2014. Asian Organization for Crohn s and Colitis. Vol.1 - Issue 1. Dear Colleagues, Dear Participants,

News Letter. Thanks letter AOCC2014. Asian Organization for Crohn s and Colitis. Vol.1 - Issue 1. Dear Colleagues, Dear Participants, Vol. - Issue Thanks letter AOCC04 Dear Colleagues, Dear Participants, On behalf of the Governing Board, I would like to express my appreciation for your dedicated participation on The Second Annual Meeting

More information

Influenza vaccination: past, present and future Christopher Blyth

Influenza vaccination: past, present and future Christopher Blyth Influenza vaccination: past, present and future Christopher Blyth School of Paediatrics and Child health, UWA Princess Margaret Hospital for Children PathWest Laboratory Medicine WA, PMH Telethon Institute

More information